|
Oct 9
|
Bio-Path Holdings Inc (BPTH) Q2 2024 Earnings Call Highlights: Financial Improvements and ...
|
|
Oct 8
|
ACHR, BPTH, PLUG, REGRF:
|
|
Oct 8
|
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
|
|
Oct 8
|
Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity
|
|
Sep 4
|
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
|
|
Aug 15
|
Bio-Path: Q2 Earnings Snapshot
|
|
Aug 15
|
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
|
|
Jun 14
|
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
|
|
May 15
|
Bio-Path Holdings Reports First Quarter 2024 Financial Results
|
|
May 8
|
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
|
|
Apr 19
|
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Apr 19
|
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
|
|
Apr 18
|
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Apr 18
|
Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
|
|
Apr 15
|
Bio-Path Holdings Expands Global Patent Portfolio
|
|
Apr 2
|
Bio-Path Holdings Provides 2024 Clinical and Operational Update
|
|
Mar 27
|
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
|
|
Mar 10
|
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript
|
|
Mar 9
|
Q4 2023 Bio Path Holdings Inc Earnings Call
|
|
Mar 8
|
Bio-Path Holdings Reports Full Year 2023 Financial Results
|